Operating Expenses Summary of FibroGen, Inc.

FibroGen, Inc.'s latest annual operating expenses in 2023 was 398.11 Million USD , down -5.54% from previous year.
FibroGen, Inc.'s latest quarterly operating expenses in 2024 Q2 was 56.38 Million USD , down -7.89% from previous quarter.
FibroGen, Inc. reported a annual operating expenses of 421.47 Million USD in annual operating expenses 2022, down -17.51% from previous year.
FibroGen, Inc. reported a annual operating expenses of 510.96 Million USD in annual operating expenses 2021, up 42.2% from previous year.
FibroGen, Inc. reported a quarterly operating expenses of 61.21 Million USD for 2024 Q1, down -19.38% from previous quarter.
FibroGen, Inc. reported a quarterly operating expenses of 86.76 Million USD for 2023 Q3, down -31.5% from previous quarter.

Annual Operating Expenses Chart of FibroGen, Inc. (2023 - 2012)

Historical Annual Operating Expenses of FibroGen, Inc. (2023 - 2012)

Year	Operating Expenses	Operating Expenses Growth
2023	398.11 Million USD	-5.54%
2022	421.47 Million USD	-17.51%
2021	510.96 Million USD	42.2%
2020	359.33 Million USD	4.23%
2019	344.74 Million USD	15.05%
2018	299.65 Million USD	20.69%
2017	248.27 Million USD	6.45%
2016	233.23 Million USD	-9.76%
2015	258.45 Million USD	37.69%
2014	187.7 Million USD	70.45%
2013	110.11 Million USD	18.21%
2012	93.15 Million USD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	56.38 Million USD	-7.89%
2024 Q1	61.21 Million USD	-19.38%
2023 Q3	86.76 Million USD	-31.5%
2023 Q4	75.92 Million USD	-12.49%
2023 Q1	108.76 Million USD	13.77%
2023 Q2	126.65 Million USD	16.46%
2023 FY	398.11 Million USD	-5.54%
2022 Q4	95.59 Million USD	-9.03%
2022 FY	421.47 Million USD	-17.51%
2022 Q3	105.08 Million USD	3.82%
2022 Q2	101.22 Million USD	-15.35%
2022 Q1	119.58 Million USD	-19.56%
2021 FY	510.96 Million USD	42.2%
2021 Q2	155.12 Million USD	47.1%
2021 Q4	148.65 Million USD	46.13%
2021 Q3	101.73 Million USD	-34.42%
2021 Q1	105.45 Million USD	-12.4%
2020 FY	359.33 Million USD	4.23%
2020 Q1	104.5 Million USD	-2.79%
2020 Q2	124.94 Million USD	19.56%
2020 Q3	9.49 Million USD	-92.4%
2020 Q4	120.38 Million USD	1167.85%
2019 Q4	107.5 Million USD	25.32%
2019 FY	344.74 Million USD	15.05%
2019 Q3	85.78 Million USD	8.94%
2019 Q2	78.74 Million USD	8.31%
2019 Q1	72.7 Million USD	-17.51%
2018 Q3	71.79 Million USD	6.85%
2018 Q4	88.13 Million USD	22.75%
2018 Q1	72.52 Million USD	9.35%
2018 Q2	67.19 Million USD	-7.35%
2018 FY	299.65 Million USD	20.69%
2017 FY	248.27 Million USD	6.45%
2017 Q3	63.28 Million USD	4.77%
2017 Q1	58.26 Million USD	-7.8%
2017 Q2	60.4 Million USD	3.68%
2017 Q4	66.32 Million USD	4.79%
2016 FY	233.23 Million USD	-9.76%
2016 Q4	63.19 Million USD	21.05%
2016 Q3	52.2 Million USD	-16.83%
2016 Q2	62.76 Million USD	13.98%
2016 Q1	55.06 Million USD	-24.45%
2015 FY	258.45 Million USD	37.69%
2015 Q4	72.88 Million USD	15.13%
2015 Q3	63.3 Million USD	3.39%
2015 Q2	61.23 Million USD	0.35%
2015 Q1	61.02 Million USD	-4.77%
2014 Q2	40.78 Million USD	27.13%
2014 Q4	64.07 Million USD	26.25%
2014 Q3	50.75 Million USD	24.45%
2014 FY	187.7 Million USD	70.45%
2014 Q1	32.08 Million USD	-14.09%
2013 Q1	4.28 Million USD	0.0%
2013 Q3	30.07 Million USD	482.45%
2013 Q2	5.16 Million USD	20.55%
2013 Q4	37.34 Million USD	24.19%
2013 FY	110.11 Million USD	18.21%
2012 FY	93.15 Million USD	0.0%

Peer Operating Expenses Comparison of FibroGen, Inc.

Name	Operating Expenses	Operating Expenses Difference
Editas Medicine, Inc.	247.3 Million USD	-60.981%
Dynavax Technologies Corporation	219.14 Million USD	-81.666%
Supernus Pharmaceuticals, Inc.	529.01 Million USD	24.744%
Perrigo Company plc	1.52 Billion USD	73.954%
Illumina, Inc.	3.81 Billion USD	89.559%
Thermo Fisher Scientific Inc.	10.25 Billion USD	96.117%
Iovance Biotherapeutics, Inc.	450.99 Million USD	11.725%
Walgreens Boots Alliance, Inc.	40.6 Billion USD	99.019%
IQVIA Holdings Inc.	2.05 Billion USD	80.608%
Heron Therapeutics, Inc.	120.65 Million USD	-229.954%
Regeneron Pharmaceuticals, Inc.	2.81 Billion USD	85.859%
Unity Biotechnology, Inc.	44.66 Million USD	-791.291%
Waters Corporation	943.51 Million USD	57.805%
Biogen Inc.	5.2 Billion USD	92.351%
Sangamo Therapeutics, Inc.	228.68 Million USD	-74.092%
Evolus, Inc.	189.75 Million USD	-109.799%
Adicet Bio, Inc.	152.03 Million USD	-161.851%
Cara Therapeutics, Inc.	142.46 Million USD	-179.45%
bluebird bio, Inc.	240.23 Million USD	-65.72%
Esperion Therapeutics, Inc.	271.89 Million USD	-46.421%
Agilent Technologies, Inc.	2.11 Billion USD	81.177%
Corbus Pharmaceuticals Holdings, Inc.	13.9 Million USD	-2762.137%
Homology Medicines, Inc.	9.87 Million USD	-3931.524%
Geron Corporation	70.44 Million USD	-465.172%
Alnylam Pharmaceuticals, Inc.	1.8 Billion USD	77.883%
Amicus Therapeutics, Inc.	427.65 Million USD	6.907%
Myriad Genetics, Inc.	600.1 Million USD	33.659%
Viking Therapeutics, Inc.	100.82 Million USD	-294.848%
Intellia Therapeutics, Inc.	551.56 Million USD	27.821%
Zoetis Inc.	2.76 Billion USD	85.602%
Abeona Therapeutics Inc.	48.5 Million USD	-720.818%
Mettler-Toledo International Inc.	1.08 Billion USD	63.455%
BioMarin Pharmaceutical Inc.	1.74 Billion USD	77.202%
Vertex Pharmaceuticals Incorporated	4.77 Billion USD	91.663%
Kala Pharmaceuticals, Inc.	39.15 Million USD	-916.814%
Ionis Pharmaceuticals, Inc.	779.58 Million USD	48.933%
Atara Biotherapeutics, Inc.	275.69 Million USD	-44.404%
Verastem, Inc.	92.08 Million USD	-332.337%
Nektar Therapeutics	190.9 Million USD	-108.542%
Axsome Therapeutics, Inc.	476.36 Million USD	16.426%
Aclaris Therapeutics, Inc.	12.14 Million USD	-3179.079%
Sarepta Therapeutics, Inc.	1.36 Billion USD	70.745%
OPKO Health, Inc.	574.68 Million USD	30.725%
Exelixis, Inc.	1.58 Billion USD	74.911%
Neurocrine Biosciences, Inc.	1.59 Billion USD	75.063%
Corcept Therapeutics Incorporated	368.61 Million USD	-8.003%
Anavex Life Sciences Corp.	55.75 Million USD	-614.027%
uniQure N.V.	285.08 Million USD	-39.647%
Imunon, Inc.	21.03 Million USD	-1793.033%
Blueprint Medicines Corporation	722.86 Million USD	44.925%
Insmed Incorporated	949.26 Million USD	58.061%
Halozyme Therapeutics, Inc.	299.31 Million USD	-33.007%
Agios Pharmaceuticals, Inc.	408.8 Million USD	2.616%
TG Therapeutics, Inc.	198.47 Million USD	-100.586%
Incyte Corporation	1.19 Billion USD	66.559%
Emergent BioSolutions Inc.	1.04 Billion USD	61.867%

Global Stocks Search

FibroGen, Inc. (0IL8.L)

Operating Expenses Summary of FibroGen, Inc.

Annual Operating Expenses Chart of FibroGen, Inc. (2023 - 2012)

Historical Annual Operating Expenses of FibroGen, Inc. (2023 - 2012)

Peer Operating Expenses Comparison of FibroGen, Inc.